

# ITI Morning Boost

April 13, 2026

\*All price's mentioned in report are based on previous day closing bases.

# NIFTY – 24,050.60 (Daily Chart)



- In Friday's trading session, the Nifty opened with a gap up and gradually moved northward, which helped the index close on a positive note.

- On a daily scale, the index has formed a bullish candle and is gradually moving toward the 50 DEMA resistance level (24,202). A decisive breakout above this level would boost bullish sentiment. However, a large gap created on 8th April remains unfilled, which will keep the bulls cautious.

- For Monday's trading session, 23,900 will act as the initial support level, while on the higher end, 24,075 will act as the initial resistance level.



# BANK NIFTY – 55,912.75 (Daily Chart)



- In Friday's trading session, the banking index opened with a gap up and gradually moved northward, which helped the index close on a positive note.

- On a daily scale, the index has formed a strong bullish candle and is gradually approaching the 50 DEMA resistance level. The index needs to breach and sustain above this level to continue its bullish momentum. However, the gap created on 8th April remains unfilled, which will keep the bulls cautious.

- **For Monday's trading session, 55,415 will act as the initial support level, while on the higher end, 56,000 will act as the initial resistance level.**



# DIVISLAB CMP- 6,116.50 ( Daily Chart)

BUY ABOVE 6,126 SL 6,065 TGT 6,250.

Divis Laboratories Limited · 1D · NSE O5,931.00 H6,130.00 L5,931.00 C6,116.50 +164.00 (+2.76%)  
Vol 334.87K  
EMA (20, close, 0, SMA, 5) 6,022.76





**M&M** : The company reported higher March 2026 production and sales, led by utility vehicles, while exports showed mixed trends across segments, according to its latest monthly filing.

CMP- 3,259.80  
IMPACT- **POSITIVE**

**LUPIN** : The pharma major has announced the launch of dapagliflozin tablets in 5 mg and 10 mg strengths in the United States. The launch follows approval of its Abbreviated New Drug Application (ANDA) from the US Food and Drug Administration (USFDA), the company said.

CMP- 2,333.80  
IMPACT- **POSITIVE**

**TORNTPHARM** : Pharmaceutical company said the US Food and Drug Administration (USFDA) inspected its Bileshwarpura (Oncology) facility in Gujarat, from April 6, 2026, to April 10, 2026.

CMP- 4,155.20  
IMPACT- **NEGATIVE**

**ADANIGREEN** : The company said its operational capacity increased 35% year-on-year to 19.3 GW in FY26 after adding 5.1 GW of greenfield capacity during the year.

CMP- 1,085.5  
IMPACT- **POSITIVE**



- America's President Donald Trump and his advisors are exploring options to break the deadlock in peace talks. This includes the possibility of limited military strikes inside Iran. The U.S. is also maintaining its blockade of the Strait of Hormuz. These actions are being considered to influence the ongoing negotiations. The Wall Street Journal reported these potential moves.
- India's coal imports saw an 8.5 percent drop in February, reaching 16.55 million tonnes. This decline was driven by high domestic coal stockpiles and firm international prices. The trend is expected to continue as domestic miners work to reduce their inventories. Coal stocks at thermal power plants remain robust, ensuring uninterrupted power generation.
- The India-UK free trade agreement is set to begin in the second week of May. This pact will allow 99 percent of Indian exports to enter Britain duty-free. Tariffs on British products like cars and whisky will also be reduced in India. A separate agreement will prevent double social levies for temporary workers. This aims to boost trade significantly.

## NIFTY50 TOP GAINERS

## NIFTY50 TOP LOSERS

Company	Price	Change	%Gain		Company	Price	Change	%Gain
Asian Paints	2,360.70	91.10	4.01		Coal India	434.10	-20.00	-4.40
Eicher Motors	7,424.00	276.50	3.87		Sun Pharma	1,654.90	-62.20	-3.62
ICICI Bank	1,321.90	40.60	3.17		Infosys	1,292.50	-39.10	-2.94
Shriram Finance	1,027.55	31.25	3.14		TCS	2,524.30	-64.70	-2.50
Bajaj Auto	9,813.50	296.50	3.12		Tech Mahindra	1,440.20	-21.40	-1.46

## NIFTY200 TOP GAINERS

## NIFTY200 TOP LOSERS

Company	Price	Change	%Gain		Company	Price	Change	%Gain
ADANIENSOL	1,157.90	79.15	7.34		Coal India	434.10	-20.00	-4.40
SONACOMS	554.25	31.20	5.97		Sun Pharma	1,654.90	-62.20	-3.62
ATGL	581.05	31.15	5.66		Coforge	1,224.30	-40.60	-3.21
SIEMENS	3,388.50	166.00	5.15		Infosys	1,292.50	-39.10	-2.94
CUMMINSIND	5,138.70	231.30	4.71		TCS	2,524.30	-64.70	-2.50

## OPEN INTEREST GAINERS

## OPEN INTEREST LOSERS

Symbol	Price	Change	Change%	Open Interest ('000)	Open Int Chg %
GODFRYPHLP	2,111.20	72.50	3.56%	46	167.74%
MPHASIS	2,337.50	-58.10	-2.43%	106.40	117.42%
CUMMINSIND	5,142.60	228.00	4.64%	65.40	75.81%
BAJAJ-AUTO	9,827.50	311.00	3.27%	105.50	72.94%
BLUESTARCO	1,681.60	1,681.60	1.98%	387	63.29%

Symbol	Price	Change	Change%	Open Interest ('000)	Open Int Chg %
BOSCHLTD	37,470.00	630.00	1.71%	7.60	-15.51%
RBLBANK	322.30	3.85	1.21%	438.20	-10.39%
ABCAPITAL	343.30	7.55	2.25%	530.10	-9.52%
VMM	114.92	2.19	1.94%	392.90	-8.99%
HAVELLS	1,283.00	24.50	1.95%	145.00	-4.61%

## INDEX HIGHEST OI

F&O Ban list	Monthly exp	Indices	Highest CE strike	Highest PE strike	PCR OI
SAIL	28/04/26	NIFTY	24,000	23,000	0.97
SAMMAANCAP	28/04/26	BANKNIFTY	60,000	58,000	0.84



## FII & DII TRADING ACTIVITY CASH

Date	FII Rs Crores			DII Rs Crores		
	Gross Purchase	Gross Sales	Net Purchase / Sales	Gross Purchase	Gross Sales	Net Purchase / Sales
Month till date	98,518.02	1,37,490.65	-38,972.63	1,39,217.72	1,03,235.19	35,982.53
10-Apr-26	18,303.96	17,631.87	672.09	15,982.46	15,572.41	410.05
09-Apr-26	15,746.32	17,457.51	-1,711.19	15,968.21	15,012.31	955.9
08-Apr-26	19,092.05	21,904.02	-2,811.97	29,003.39	24,835.22	4,168.17
07-Apr-26	7,953.46	16,645.57	-8,692.11	20,860.09	12,880.59	7,979.50

## FII & DII TRADING ACTIVITY STOCK F&O

Date	FII Stock Fut			FII Stock Opt		
	Gross Purchase	Gross Sales	Net Purchase / Sales	Gross Purchase	Gross Sales	Net Purchase / Sales
Month till date	1,47,894.48	1,42,046.51	5,847.97	9,02,776.07	9,07,662.19	-4,886.12
10-Apr-26	22,881.01	22,478.22	402.79	18,581.81	19,468.12	-886.31
09-Apr-26	21,873.97	21,998.25	-124.28	17,872.87	18,331.29	-458.42
08-Apr-26	34,009.70	31,487.91	2,521.79	17,583.70	17,563.92	19.78
07-Apr-26	19,991.33	20,571.63	-580.3	11,454.01	11,241.81	212.2



## TOP SECTORS PERFORMANCE OF THE DAY

Name	Daily (%)	1 Week (%)	1 Month (%)	3 Months (%)	6 Months (%)	1 Year (%)
Edible Oil	4.87	4.88	10.52	-3.13	-12.31	4.69
Ship Building	4.2	10.91	-1.47	-1.54	97.08	866.38
Telecom-Service	3.74	9.48	3.29	-12.81	-20.72	-7.8
Refractories	3.29	8.48	3.28	-13.63	-11.73	10.55
Quick Service Restaurant	3.28	6.21	-1.05	-8.99	-22.43	-17.33



## Result calendar for F&O stocks

09-04-2026	14-04-2026	15-04-2026	16-04-2026	18-04-2026
TCS	ICICIPRULI	ICICIGI	HDFCAMC	HDFCBANK
			ANGELONE	ICICIBANK
			HDFCLIFE	
			WIPRO	

# UPCOMING ECONOMIC EVENTS

Monday, 13 April 2026	Country	Event's	Forecast		Previous
16:00	IN	CPI (YoY) (Mar)	3.48%		3.21%
19:30	US	Existing Home Sales (Mar)	4.07M		4.09M
Tuesday, 14 April 2026					
12:00	IN	WPI Inflation (YoY) (Mar)	3.10%		2.13%
18:00	US	PPI (MoM) (Mar)	1.2%		0.7%
Wednesday, 15 April 2026					
14:30	IN	Trade Balance (Mar)	-32.75B		-27.10B
16:00	IN	CPI (YoY) (Mar)	3.48%		3.21%
20:00	US	Crude Oil Inventories			3.081M

## Disclaimer

This report has been prepared by ITI Securities Broking Limited (hereinafter referred to as ITISBL) to provide information about the company(ies) and/or sector(s), if any, covered in the report and may be distributed by it and/or its affiliated company(ies). ITISBL is a Stock Broker and Depository Participant registered with and regulated by Securities & Exchange Board of India. ITISBL and its affiliates are a full-service, integrated investment banking, investment management, brokerage and financing group.

This report is for personal information of the selected recipient/s and does not constitute to be any investment, legal or taxation advice to you. This research report does not constitute an offer, invitation or inducement to invest in securities or other investments and ITISBL is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your general information and should not be reproduced or redistributed to any other person in any form. This report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, investors should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. We and our affiliates have investment banking and other business relationships with a some companies covered by our Research Department. Our research professionals may provide input into our investment banking and other business selection processes. Investors should assume that ITISBL and/or its affiliates are seeking or will seek investment banking or other business from the company or companies that are the subject of this material and that the research professionals who were involved in preparing this material may educate investors on investments in such business. The research professionals responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting information. Our research professionals are paid on the profitability of ITISBL which may include earnings from investment banking and other business.

ITISBL generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, ITISBL generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover. Our salespeople, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing among other things, may give rise to real or potential conflicts of interest. ITISBL and its affiliated company(ies), their directors and employees and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the affiliates of ITISBL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report. Reports based on technical and derivative analysis center on studying charts company's price movement, outstanding positions and trading volume, as opposed to focusing on a company's fundamentals and, as such, may not match with a report on a company's fundamental analysis. In addition ITISBL has different business segments / Divisions with independent research separated by Chinese walls catering to different set of customers having various objectives, risk profiles, investment horizon, etc, and therefore may at times have different contrary views on stocks sectors and markets.

Unauthorized disclosure, use, dissemination or copying (either whole or partial) of this information, is prohibited. The person accessing this information specifically agrees to exempt ITISBL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold ITISBL or any of its affiliates or employees responsible for any such misuse and further agrees to hold ITISBL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays. The information contained herein is based on publicly available data or other sources believed to be reliable. Any statements contained in this report attributed to a third party represent ITISBL's interpretation of the data, information and/or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party. This Report is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. While we would endeavour to update the information herein on reasonable basis, ITISBL and/or its affiliates are under no obligation to update the information. Also there may be regulatory, compliance, or other reasons that may prevent ITISBL and/or its affiliates from doing so. ITISBL or any of its affiliates or employees shall not be in any way responsible and liable for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. ITISBL or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations. This report is intended for distribution to investors. Recipients who are not investors should seek advice of their independent financial advisor prior to taking any investment decision based on this report or for any necessary explanation of its contents ITISBL and its associates may have managed or co-managed public offering of securities, may have received compensation for investment banking or merchant banking or brokerage services, may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. ITISBL and its associates have not received any compensation or other benefits from the subject company or third party in connection with the research report. Subject Company may have been a client of ITISBL or its associates during twelve months preceding the date of distribution of the research report. ITISBL and/or its affiliates and/or Research analyst / or relative of research analyst or Employees may have interests/positions, financial or otherwise of over 1% at the end of the month immediately preceding the date of publication of the research in the securities mentioned in this report. To enhance transparency, ITISBL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. Neither the Research Analysts nor ITISBL have been engaged in market making activity for the companies mentioned in the report. ITISBL and/or its affiliates and/or Research analyst/ relative of research analyst have not any material conflict of interest at the time of publication of this report. There are no material disciplinary action that been taken by any regulatory authority impacting equity research analysis activities Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

### Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The research analysts, strategists, or research associates principally responsible for preparation of ITISBL research receive compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues

### Disclosure of Interest Statement - Companies where there is interest

Analyst ownership of the stock: No

Served as an officer, director or employee: No

### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ITISBL & its group companies to registration or licensing requirements within such jurisdictions.

ITI Securities Broking Limited

SEBI – Research Analyst REG. NO. : INH000001535

SEBI REG. NO: NSE&BSE: INZ000005835, CDSL-IN-DP-70-2015, AMFI Reg. No. ARN-12576,

CIN NO: U74120MH1994PLC077946

ITI House, 36, Dr. R. K. Shirodkar Road,

Parel, Mumbai - 400 012,

Boardline - (91) 22 69093600 Fax- 022 69093700

For queries, write to us at [iti.research@itiorg.com](mailto:iti.research@itiorg.com)